Drug Trial Radar · NCT03913195
Study of the Safety of Trogarzo™ Administered as an Undiluted "IV Push" or an Intramuscular Injection
Last checked: Nov 20, 2026Latest source record: Oct 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
43
Actual
Start
May 30, 2019
Primary completion
Oct 17, 2022
Study completion Oct 31, 2022
Sponsor
- Lead sponsor
- TaiMed Biologics Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Westat
- First posted
- Apr 12, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is designed to assess the safety and pharmacokinetic profile of 800 mg Trogarzo once every two weeks administered via "IV Push" or intramuscular injection. An initial "Sentinel Group" of 5 participants will begin receiving 800mg Trogarzo on a gradual schedule of increasing concentration and decreasing administration time until undiluted IV Push over 30 seconds is achieved, while safety and pharmacokinetics are evaluated. If no safety signals are seen, the Core Group of 15 participants will be enrolled. The Core Group will receive 800mg Trogarzo via undiluted IV Push over 30 seconds while safety and pharmacokinetics are monitored. After completion of the IV Push portion of the study, a second group of 20 participants will be enrolled to evaluate the safety and pharmacokinetics of administration of 800mg via intramuscular injection.
Conditions
- HIV-1-infection
Interventions
ibalizumab-uiykDrug
Ibalizumab-uiyk is an Immunoglobulin G4 (IgG4) monoclonal antibody targeting domain 2 of the extracellular portion of the Cluster of Differentiation 4 (CD4) protein. Ibalizumab-uiyk is FDA approved for the treatment of multi-drug resistant HIV in treatment experienced patients.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety of Trogarzo Given as IV Push Over 30 SecondsTime frame: 12 weeks
- Pharmacokinetics Bridge for IV Push and IV Infusion (Ctrough)Time frame: Day 1 infusion versus Day 85 IV Push
- Pharmacokinetics Bridge for IV Push and IV Infusion (AUC)Time frame: Day 1 infusion versus Day 85 IV Push
- Safety of Trogarzo Given as an Intramuscular Injection in the Intramuscular Injection GroupTime frame: 10 weeks
- Pharmacokinetics Bridge Demonstrated for Intramuscular Injection of Trogarzo and IV InfusionTime frame: Day 1 infusion versus Day 71 intramuscular injection
Locations
4 sites in 1 country. Site status is shown where the registry gives one.
Anthony Mills MD Inc.
Los Angeles, California
Gary Richmond MD, PA
Fort Lauderdale, Florida
Orlando Immunology Center
Orlando, Florida
North Texas Infectious Disease Consultants
Dallas, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.